Company Overview and News
Thank you for holding and welcome to the Titan Pharmaceuticals Third Quarter 2017 Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session following today’s remarks. Please be advised that this call is being taped at the Company’s request and will be archived on the Company’s website starting later today. (19-0)
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (58-0)
* Opiant Pharmaceuticals says may offer & sell through Cantor Fitzgerald its shares having aggregate offering price of up to $25 million - SEC filing Source text (bit.ly/2gQyRPi) Further company coverage: (Bangalore.email@example.com) (3-0)
* Opiant Pharmaceuticals Inc files for mixed shelf of upto $150 million - sec filing Source text : bit.ly/2gmIQz2 Further company coverage: (3-0)
* Opiant Pharmaceuticals Inc reports fiscal fourth quarter and full year 2017 financial results and provides corporate update (3-0)
LONDON, UK / ACCESSWIRE / October 4, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=TTNP. The Company announced on October 02, 2017, collaboration with Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) for exploring an innovative approach for the prevention of opioid relapse and overdose in individuals with opioid use disorder. (34-0)
* Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment (19-0)
LONDON, UK / ACCESSWIRE / September 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) ("Opiant"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=OPNT. The Company announced on September 15, 2017, an update on the NARCAN Nasal Spray. (20-0)
Research and Markets has announced the addition of the "CNS Cluster Addiction Drug Development Pipeline Review, 2017" report to their offering.
LONDON, May 29, 2017 /PRNewswire/ -- Summary This report provides an overview of the CNS Clusters pipeline landscape. The report provides comprehensive information on the therapeutics under development, and key players involved in therapeutic development for Alcohol Addiction, Drug Addiction, Nicotine Addiction, Opium (Opioid) Addiction and features dormant and discontinued projects. Alcohol addiction refers to a psychological and physical dependency on alcohol.
Opiant Pharmaceuticals (NASDAQ:OPNT) sells the rights to certain royalties and milestone payments related to sales of NARCAN Nasal Spray to SWK Holdings for $17.5M. The company received $13.7M at closing and is eligible to receive an additional $3.75M if certain sales-based milestones are achieved.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Interception of Extracellular Tau by Antibodies May Be Sufficient to Stop the Spread of Tau in AD
In compiling the Dividend Champions list (found here: http://dripinvesting.org/Tools/Tools.asp) I get to see which companies are nearing the anniversaries of their previous dividend increases. Since m
The mantra continues to be that cash is king. This mantra highlighted companies with cash on the balance sheet and generating strong cash flows, but it placed no emphasis on the use of that cash. Now
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton